CTOs on the Move

Phathom Pharmaceuticals

www.phathompharma.com

 
Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Phathom Pharmaceuticals raised $50M on 05/15/2019
Phathom Pharmaceuticals raised $90M on 05/15/2019

Similar Companies

Chromocell, Corporation

Chromocell, Corporation is a North Brunswick, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SunMed

Select SunMed for Anesthesia and Respiratory Care SolutionsDedicated to Improving Quality of LifeWho Is SunMedSelect SunMed for Your Place to GrowDedicated to Improving Quality of LifeCareers with SunMedSelect SunMed for Medical Device ManufacturingDed...

Bristol-Myers Squibb Canada

Bristol-Myers Squibb Canada is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Myonexustx

Myonexus Therapeutics is a clinical stage, rare disease gene therapy company developing first-ever, corrective treatments for Limb-girdle muscular dystrophy.

SOLESIS

Solesis is an innovative provider of biomaterials solutions and services primarily focused on the medical device and advanced therapy industries.